Dark Horse Technology Group embarks on major asset restructuring with multiple acquisitions

Today, significant developments unfolded in the Shenzhen market, particularly with major asset restructuring initiatives and regulatory updates affecting several companies.

Deals & Restructuring

• Dark Horse Technology Group Co., Ltd. (300688) is initiating a substantial asset restructuring involving the issuance of shares and cash payments to acquire assets from multiple counterparties, including Beijing Digital Certification Co., Ltd. and Beijing Cloud Gate Information Security Technology Co., Ltd. The company aims to raise supporting funds from up to 35 specific investors, pending regulatory approval.
• Wuhan Easy Diagnosis Biomedicine Co., Ltd. (002932) has completed the acquisition of 100% equity in Wuhan Biker Rescue Supplies Co., Ltd. from Blue Sail Medical Co., Ltd. for 190 million RMB, confirming the completion of all legal procedures related to the transaction.
• Xintian Technology Co., Ltd. (300615) reported a change in equity following a share transfer agreement, where Shenzhen Yuanqi Infinite Technology Partnership is acquiring 22.50% of the company's total share capital. This transaction is subject to compliance confirmation by the Shenzhen Stock Exchange.

Regulatory & Governance

• ST Cuihua Co., Ltd. (002731) announced the progress of an investigation into alleged false financial information, which may lead to mandatory delisting. The company has failed to disclose its 2025 annual report on time, issuing its sixth risk warning regarding potential delisting.
• Fibocom Wireless Inc. (300638) received a decision from the State Administration for Market Regulation allowing its acquisition of a 37.16% stake in Shenzhen HOSUN Electronics Co., Ltd. to proceed, pending shareholder approval.
• Dark Horse Technology Group Co., Ltd. (300688) also provided responses to inquiries from the Shenzhen Stock Exchange regarding its asset acquisition and fundraising application, addressing concerns about related-party transactions.

Earnings & Performance

• CSPC Innovation Pharmaceutical Co., Ltd. (300765) released its 2026 interim report, confirming no dividend distribution or capital reserve capitalization for this period, while detailing management discussions and risk assessments.
• Zhongjing Food Co., Ltd. (300908) reported an 8.01% increase in operating revenue to 566.45 million RMB for the first half of 2026, with a net profit rise of 7.75% to 108.32 million RMB.

Other Notable Developments

• Betta Pharmaceuticals Co., Ltd. (300558) announced initial trial data from the DURAVYU™ Phase III trial for wet AMD, noting that while primary endpoints were not met, secondary endpoints related to safety were achieved.
• Jones Tech Plc (300684) reported abnormal stock trading fluctuations due to a 100% price increase over 10 trading days, confirming no undisclosed material information.
• Guangdong Haomei New Material Co., Ltd. (002988) plans to jointly invest with professional institutions to establish an industrial fund with a target size of RMB 1 billion, contributing RMB 100 million as a limited partner.

These announcements reflect a dynamic day in the Shenzhen market, with companies actively pursuing growth through strategic acquisitions and navigating regulatory challenges.